UGT1A1 and metabolic dysfunction-associated steatotic liver disease: The study found no significant association between GS and the presence of MASH or the degree of hepatic fibrosis in patients with MASLD.Future large-scale, prospective longitudinal cohort studies incorporating serial liver elastography assessments, advanced imaging modalities, and UGT1A1 genotyping are needed to better understand whether GS influences the progression of MASLD.